Current Medical Research and Opinion最新文献

{"title":"Utilization of colorectal cancer screening modalities in the United States (2017-2023): a national multi-payer claims database analysis.","authors":"Mallik Greene, Shrey Gohil, Brad Stieber, A Burak Ozbay, Quang A Le, Raja Kakuturu, Joseph W LeMaster, Michael Dore, A Mark Fendrick, Joseph C Anderson, Jordan J Karlitz","doi":"10.1080/03007995.2025.2565442","DOIUrl":"10.1080/03007995.2025.2565442","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the second leading cause of U.S. cancer mortality. This study evaluated the utilization of CRC screening modalities from 2017 to 2023.</p><p><strong>Methods: </strong>This retrospective, cross-sectional study analyzed data from 2017 to 2023 using a national multi-payer claims database, supplemented with laboratory data related to CRC screening. Patients aged 45-75 years, at average risk for CRC, with no prior CRC diagnosis, and who had continuous health insurance enrollment for 24 months (from January 1 of the baseline year to December 31 of the study year) were included. Annual proportions for colonoscopy, multi-target stool DNA (mt-sDNA) test, fecal immunochemical test/fecal occult blood test (FIT/FOBT), and other modalities were assessed, along with sociodemographic factors. Descriptive statistics and chi-square tests were used to assess utilization trends across the years.</p><p><strong>Results: </strong>Colonoscopy remained the most commonly used screening modality, with its share increasing slightly from 53.0% in 2017 to 58.7% in 2023. The mt-sDNA test proportion increased significantly from 2.4% in 2017 to 20.4% in 2023, while the proportion of FIT/FOBT declined significantly, from 44% to 20.4%. Similarly, significant age-related shifts in screening utilization were observed, with colonoscopy proportion increasing from 48.1% to 61.6%, mt-sDNA rising from 0.0% to 24.0%, and FIT/FOBT declining from 50.8% to 14.1% in the 45-49 age group from 2017 to 2023.</p><p><strong>Conclusion: </strong>CRC screening utilization shifted significantly from 2017 to 2023, with increased colonoscopy and mt-sDNA use and a marked decline in FIT/FOBT. Continued monitoring is critical to ensure equitable access to effective modalities.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical burden and healthcare resource utilization of patients with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia in the Netherlands.","authors":"Jennifer Drahos, Flávia Soares Peres, Naomi Reimes, Frederiek van Pinxteren, Jetty Overbeek, Duncan Brown, Nanxin Li, Bart J Biemond","doi":"10.1080/03007995.2025.2567964","DOIUrl":"https://doi.org/10.1080/03007995.2025.2567964","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to describe the clinical burden and healthcare resource utilization (HCRU) among patients with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOCs) and patients with transfusion-dependent β-thalassemia (TDT) in the Netherlands.</p><p><strong>Methods: </strong>This retrospective cohort study identified two patient populations, one cohort with SCD and recurrent VOCs and the other with TDT from the PHARMO Data Network (January 1, 2014-December 31, 2020). Key inclusion criteria were diagnosis of SCD and ≥2 VOCs per year for 2 consecutive years following the diagnosis for SCD; or diagnosis of β-thalassemia and ≥8 red blood cell transfusions (RBCTs) per year for 1 year following the diagnosis for β-thalassemia. Complications and HCRU were evaluated for each cohort.</p><p><strong>Results: </strong>A total of 383 patients with SCD and recurrent VOCs and a total of 54 patients with TDT were identified with mean ages at index of 26.9 (standard deviation [SD]: 14.4) years and 17.7 (SD: 15.2) years, respectively. Patients with SCD and recurrent VOCs experienced an average of 7.0 VOCs per patient per year (PPPY). The most common acute complication was acute chest syndrome (34.9%), and the most common chronic complications were bone and joint complications (12.0%). Patients had a mean of 2.5 inpatient hospitalizations and 7.0 outpatient visits PPPY.Patients with TDT (n = 54) received an average of 13.0 RBCTs PPPY. The most common acute complication was infection (5.6%), and the most common chronic complication was transfusion-induced iron overload (33.3%). Patients had a mean of 11.3 inpatient hospitalizations, mainly driven by transfusion-related hospitalizations, and 8.4 outpatient visits PPPY.</p><p><strong>Conclusion: </strong>Patients with SCD and recurrent VOCs and patients with TDT in the Netherlands sustain substantial clinical complications and HCRU mainly related to VOCs and regular RBCTs, respectively.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of serum phosphate control in supporting transplant readiness in patients on dialysis.","authors":"Laura A Williams, Stephen Z Fadem","doi":"10.1080/03007995.2025.2563377","DOIUrl":"10.1080/03007995.2025.2563377","url":null,"abstract":"<p><p>Chronic kidney disease affects over 36 million Americans, with more than 800,000 progressing to end-stage kidney disease (ESKD). Treatment with kidney transplantation offers superior survival, quality of life, and cost-effectiveness compared with dialysis, yet access remains limited. Hyperphosphatemia is a highly prevalent and modifiable complication of ESKD that contributes to cardiovascular disease, mineral bone disorder, and potential pulmonary dysfunction. Additionally, elevated serum phosphate has been linked to transplant graft failure and adverse post-transplant outcomes. Although normal phosphate levels are not formally required for transplant eligibility, they are frequently considered as part of transplant readiness assessments. Persistent gaps between clinical guideline recommendations and real-world serum phosphate control, despite dialysis, dietary restrictions, and phosphate binder therapy, underscore the need for individualized and more effective treatment strategies. Because transplant candidacy may be influenced by serum phosphate levels, phosphate management should be viewed not just as correction of a laboratory abnormality, but as a strategy to improve transplant access, promote health equity, and enhance long-term outcomes. Real-world tracking of transplant readiness metrics by serum phosphate levels will be essential to assessing the impact of new therapies and support transparent and equitable organ allocation. Effective phosphate management may reduce time on dialysis, improve graft and patient survival, and lower healthcare costs. In this context, managing hyperphosphatemia is a clinical and strategic imperative in advancing kidney health.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated plasma aldosterone concentrations relate to renal impairment in Chinese southwestern people.","authors":"Boteng Yan, Chaoyan Tang, Shengzhu Huang, Yushuang Wei, Mingjie Xu, Xihui Jin, Xiaoyou Mai, Lingyu Ye, Zengnan Mo, Mingli Li","doi":"10.1080/03007995.2025.2565441","DOIUrl":"https://doi.org/10.1080/03007995.2025.2565441","url":null,"abstract":"<p><strong>Background: </strong>Evidence on the biochemical phenotypes of primary aldosteronism and renal functions is limited in Chinese. Our study aims to explore the associations of plasma aldosterone concentration (PAC), plasma renin concentration (PRC), and aldosterone-to-renin ratio (ARR) with renal functions.</p><p><strong>Methods: </strong>This cross-sectional study enrolled 1,700 participants from southwest China. A generalized linear mixed model (GLMM) was employed to analyze the associations of PAC, PRC and ARR with renal function parameters: serum creatinine (SCR), blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR), their dose-response relationships were further assessed using P-trend and restricted cubic spline (RCS) analyses. The mediating effects of blood pressure on the associations between PAC and renal function were evaluated using structural equation model (SEM).</p><p><strong>Results: </strong>In the overall cohort, GLMM results indicated that higher 1-log PAC were associated with elevated levels of SCR (β [95% CI] = 0.451 [0.329, 0.573]) and BUN (β [95% CI] = 0.370 [0.278, 0.462]), lower eGFR (β [95% CI] = -0.263 [-0.331, -0.194]). Furthermore, RCS supported a positive linear association between PAC with SCR and BUN, but a negative linear association with eGFR. Compared with the female subgroup, a relatively stronger significant association is observed between PAC with SCR and BUN in the male subgroup. Noticeably, the use of Renin-Angiotensin-Aldosterone (RAS) inhibitors can mitigate the positive effects of PAC on BUN. Additionally, systolic blood pressure played a slightly mediated effect on association of PAC with SCR and eGFR, with the mediation proportions were 2.4% and 2.6%, respectively.</p><p><strong>Conclusion: </strong>Our study found a continuum spectrum of PAC is associated with renal impairment, particularly in males, and the use of RAS inhibitors can alleviate renal function impairment to a certain extent.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implantation, removal, and adjustment of the totally implantable venous access port under the guidance of digital subtraction angiography: a ten-year experience at a territory medical center.","authors":"Yingliang Wang, Huimin Zhou, Chen Zhou, Yaowei Bai, Xiangjun Dong, Xiangwen Xia, Chuansheng Zheng","doi":"10.1080/03007995.2025.2563380","DOIUrl":"10.1080/03007995.2025.2563380","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to report the 10-year experience of implantation, removal, and adjustment of a totally implantable venous access port (TIVAP) under the guidance of digital subtraction angiography (DSA) at a territory medical center.</p><p><strong>Methods: </strong>The medical records of consecutive patients who underwent implantation, removal, and adjustment of the TIVAP under DSA guidance from January 2014 to March 2024 were retrospectively reviewed.</p><p><strong>Results: </strong>In total, 290 consecutive patients who underwent TIVAP implantation were included, of which, 136 (46.9%) were men and 154 (53.1%) were women, with a mean age of 44.4 ± 16.5 years. The mean radiation dose was 4.9 ± 1.4 mGy. The operation time was 34.1 ± 3.8 min. The technical success rate was 100%. During a median follow-up of 239 days, 9 cases showed complications. No significant differences were found in age, sex, operation time, and radiation dose between the subclavian vein (SCV) and internal jugular vein (IJV) groups, while there were fewer complications in the IJV group (<i>p</i> = 0.039), and 114 consecutive patients who underwent TIVAP removal were included, of which, 49 (43.0%) were men and 65 (57.0%) were women, with a mean age of 44.3 ± 15.4 years. The median radiation dose was 3.8 (1.3-62.3) mGy. The median interval time from implantation to removal was 358.5 (2-3650) days. The operation time was 34.4 ± 6.1 min. The technical success rate was 100%. No significant differences were observed between the SCV and IJV groups. Cases with fracture and dislocation of the catheters were defined as the complicated group, while the others were defined as the uncomplicated group. The operation time (45.7 ± 12.4 vs. 33.7 ± 4.6 min) and radiation dose (45.4 ± 10.8 vs. 4.2 ± 2.2 mGy) between the above two groups were significantly different (both <i>p</i> < 0.05); A total of nine consecutive patients who underwent adjustment of the TIVAP were included, of which three patients had dislocation of the catheter and six patients had kinking of the catheters. They were all successfully adjusted using a pigtail catheter and/or gooseneck snare. The average operation time and radiation dose were 20.8 ± 5.6 min and 3.2 ± 1.3 mGy.</p><p><strong>Conclusion: </strong>Implantation, removal, and adjustment of the venous port access under DSA guidance were safe and efficient. For the removal and adjustment of complicated cases, using the pigtail catheter and/or gooseneck snare under DSA guidance was efficient. In addition, the IJV seems to be a safer venous access site with a lower complication rate than the SCV.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease burden, comorbidities, and treatment patterns of patients with multiple myeloma in Dubai: a retrospective analysis of the Dubai real-world claims database.","authors":"Faraz Khan, Mohamed Farghaly, Ali Aljabban, Mostafa Zayed, Kumaresan Subramanyam, Badarinath Chickballapur Ramachandrachar","doi":"10.1080/03007995.2025.2560656","DOIUrl":"10.1080/03007995.2025.2560656","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to evaluate the disease burden, comorbidities, specialties consulted, and treatment pattern, in patients with multiple myeloma (MM) in Dubai, United Arab Emirates (UAE).</p><p><strong>Methods: </strong>This study analyzed data from the Dubai Real-World Claims Database (DRWD) from 01 January 2014 to 30 June 2023. Patients with at least one diagnosis claim for MM and continuous enrollment were included. Patients were stratified into 3 cohorts, based on their most recent treatment response status; Not achieved remission, Remission and Relapse.</p><p><strong>Results: </strong>Of 1,126 MM patients, most were aged 40-60 years. Not achieved remission was the predominant cohort with 431 patients. The number of new and reported MM patients ranged between 2.6 to 4.2 and 2.9 to 4.7 per 100,000 population, respectively, during the index period. The most prevalent comorbidities were diabetes and cardiovascular diseases (88.3%), followed by renal disease (27.9%), neuropathy (24.6%), and infections (24.0%). Only 34.1% (<i>n</i> = 251) of patients received MM treatment; 35 had undergone bone marrow transplantation and 153 had received systemic treatment. The most common regimen was bortezomib combined with lenalidomide plus dexamethasone or dexamethasone alone in 33% of the non-transplant and 50% of transplant patients. Most patients consulted internal medicine (28.7%), oncology (19.7%), and hematology (15.9%).</p><p><strong>Conclusion: </strong>The study highlights the increasing trend in the disease burden and gaps in treatment patterns in patients with MM, using real-world data from Dubai-a region with a large expatriate population. Study findings emphasize the need for health policies that prioritize the establishment of patient registries and the development of subsidized care pathways.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of healthcare visits and vaccination among adolescents and young adults 16-23-years-old: a retrospective US claims database analysis.","authors":"Oscar Herrera-Restrepo, Jasjit K Multani, Zifan Zhou, Queenie Paltanwale, Tosin Olaiya, Anna D Coutinho, Rajeev B Shah, Chi-Chang Chen","doi":"10.1080/03007995.2025.2556983","DOIUrl":"10.1080/03007995.2025.2556983","url":null,"abstract":"<p><strong>Objective: </strong>Several vaccines are recommended for 16-23-year-olds in the United States, but coverage varies widely across these vaccines. Previous studies have indicated that routine healthcare visits are associated with vaccination uptake. This study aimed to describe healthcare visit patterns among 16-23-year-olds to identify challenges and inform opportunities to reach adolescents and young adults for vaccination.</p><p><strong>Methods: </strong>A descriptive, retrospective database analysis was conducted of commercially insured and Medicaid-insured 16-23-year-olds from 2019-2022 using IQVIA's PharMetrics^® Plus claims database and open-source Longitudinal Prescription/Medical claims databases. The proportion of 16-23-year-olds with healthcare provider (HCP) visits, visit types, provider types involved, visits including vaccination, and specific vaccines delivered were analyzed.</p><p><strong>Results: </strong>In 2022, 68.2% of commercially insured 16-23-year-olds had ≥1 HCP visit. Most commercially insured and Medicaid-insured individuals with ≥1 HCP visit had sick visits (72.9-80.6%). The proportion of individuals with preventative visits was lower as age increased (commercially insured: 73.2% at 16, 67.4% at 18, 56.3% at 19, and 45.3% at 23 years). Lower proportions of individuals with preventative visits with increasing age were also seen among Medicaid-insured individuals, ranging from 53.7% at 16 years to 28.0% at 23 years. Among 16-18-year-olds with ≥1 HCP or pharmacy visit in 2022, 52.6% in the commercial cohort and 33.0% in the Medicaid cohort had ≥1 visit that involved vaccination; for 19-23-year-olds, these proportions were 34.5% and 25.6%, respectively. Vaccination rates by vaccine type were largely aligned with the ages specified by recommendations, but nonetheless were low.</p><p><strong>Conclusion: </strong>Approximately one-third of commercially insured 16-23-year-olds did not have an annual HCP visit, and among commercially insured and Medicaid-insured individuals who did have visits, a substantial proportion did not have preventative visits; this proportion was higher with increasing age. The proportions of visits with vaccination were particularly low for 19-23-year-olds. Targeted interventions to promote routine visits, including framing these as opportunities for immunization, may help to increase vaccination uptake; based on the findings of this analysis, these efforts should consider age-specific shifts in health-seeking behaviors.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-15"},"PeriodicalIF":2.2,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/03007995.2025.2563475","DOIUrl":"https://doi.org/10.1080/03007995.2025.2563475","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan.","authors":"Masashi Takano, Kazuko Suzuki, Sakiyo Tsukamoto, Yasuo Nakajima, Hirofumi Ozeki, Masao Yarita, Ai Hayashi","doi":"10.1080/03007995.2025.2556321","DOIUrl":"https://doi.org/10.1080/03007995.2025.2556321","url":null,"abstract":"<p><strong>Objective: </strong>HIF-PHI inhibitors, including daprodustat, have expanded treatment options for patients with renal anaemia in Japan. This analysis examines real-world utilization of daprodustat in Japan, for which data are currently lacking.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed patient characteristics, treatment patterns, and management of renal anaemia in individuals aged >15 years who were treated with daprodustat between 1 August 2020 and 1 July 2023 using an anonymized electronic medical record database. Patients were assigned to dialysis-dependent (DD) and nondialysis-dependent (ND) cohorts.</p><p><strong>Results: </strong>This study included 1299 patients (111 DD cohort; 1188 ND cohort). Mean age was 71.0 and 79.2 years in the DD and ND cohorts, respectively. In both cohorts, hypertension, heart failure, oesophageal gastric erosion, and type 2 diabetes mellitus were frequent comorbidities. In the DD cohort, 31.5% of patients had Hb levels of 9-10 g/dL at baseline and in the ND cohort 35.9% had Hb levels <9 g/dL at baseline. Prior to the index date, 72 patients in the DD cohort (64.9%) and 635 patients (53.5%) in the ND cohort were treated for anaemia. In patients who switched from erythropoiesis-stimulating agents to daprodustat, mean haemoglobin increased from 9.9 g/dL at baseline to 10.8 g/dL in the DD cohort (<i>n</i> = 23; Wilcoxon sign-ranked test [WSRT] <i>p</i> = 0.0148) and from 9.6 g/dL at baseline to 10.4 g/dL in the ND cohort (<i>n</i> = 92; WSRT <i>p</i> < 0.0001) 28 weeks after daprodustat initiation.</p><p><strong>Conclusion: </strong>Approximately a third (DD) to almost half (ND) of patients with renal anaemia were not receiving treatment for anaemia. An increase in haemoglobin levels was observed after initiation of daprodustat, including in patients previously treated with erythropoiesis-stimulating agents, however causality cannot be confirmed due to lack of a control group.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose influenza vaccine for elderly: a closer look into the real-world data.","authors":"Laura Colombo, Anna Elisabeth Steinberg, Sanjay Hadigal","doi":"10.1080/03007995.2025.2559871","DOIUrl":"10.1080/03007995.2025.2559871","url":null,"abstract":"<p><p>Older adults are at increased risk of severe illness, hospitalization, and death due to influenza, making vaccination a key public health strategy. High-dose (HD) influenza vaccine has been recommended in several European countries to enhance protection in this vulnerable group. While clinical trials and observational studies have reported improved effectiveness of HD vaccine in preventing influenza-related outcomes, this advantage appears most consistent in individuals aged 75 and older. In contrast, evidence supporting the superiority of HD vaccine over standard-dose (SD) vaccines in the 65-74 age group (the \"young-old\") is limited and often not statistically significant. This review examined real-world effectiveness data comparing HD and SD influenza vaccines in elderly populations. While HD vaccines may provide added protection in the oldest age groups, SD vaccines continue to offer substantial and reliable protection, particularly among the 60-74 age range. HD vaccine is associated with higher rates of mild side effects and carries a significantly greater cost, which may limit its cost-effectiveness for broad use in the younger elderly population. Given that the majority of elderly individuals in developed countries fall within the 65-74 age group, a tailored vaccination approach may be more appropriate. Recommending HD vaccine primarily for those aged 75 and older, while offering SD vaccines to younger seniors, may help increase vaccine coverage without compromising protection. More real-world, age-stratified studies are needed to guide vaccination policies. Ultimately, any influenza vaccine is better than none, and SD vaccines remain an effective and accessible option for most older adults.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}